Created specifically for von Willebrand disease (VWD) bleeding episodes1
VONVENDI is the first and only recombinant treatment for adults with VWD.2 It helps control bleeds both on-demand and prevent excessive bleeding in surgery.1
Key facts about VONVENDI
Manufactured without human blood or plasma
VONVENDI is recombinant, meaning it's made without using human blood. This technology avoids the risk of spreading diseases through infected human blood.3
Can be used with or without recombinant FVIII as directed
Depending on your specific situation, your healthcare provider will decide if you may use VONVENDI by itself, or if you require additional recombinant FVIII (rFVIII).1
Approved for two separate uses
Your healthcare provider may prescribe VONVENDI for two different uses: on-demand treatment of bleeds and to prevent excessive bleeding during and after surgery.1
On-demand
VONVENDI can be used on-demand by adults with VWD to control major and minor bleeds in all locations, including mouth bleeds, nosebleeds, heavy menstrual bleeds, GI bleeds, and joint bleeds.1
VONVENDI is infused into your blood stream, where it acts like your body's natural von Willebrand factor (VWF), helping to form clots, and helping your own FVIII to work.1
VONVENDI® side effects
Always talk to your healthcare provider before taking any prescription medication, including VONVENDI. Learn more about VONVENDI side effects and safety.
We use cookies to ensure that we give you the best experience possible. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice. For more information on the cookies we use and how to delete or block the use of cookies, read our cookie policy.
VONVENDI is used in adults (age 18 years and older) diagnosed with von Willebrand disease to:
treat and control bleeding episodes
prevent excessive bleeding during and after surgery
Who should not use VONVENDI?
You should not use VONVENDI if you:
Are allergic to any ingredients in VONVENDI
Are allergic to mice or hamsters
References
VONVENDI Prescribing Information
Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment
Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
You're now leaving this site
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.